Stockreport

Dark Blue Therapeutics acquired by Amgen for up to $840 million

Amgen Inc.  (AMGN) 
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PDF Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid LeukemiaAcquisition brings a new therapeu [Read more]